Posted by Rick on June 3, 2001, at 15:18:52
In reply to Re: Studies: New Celexa+others promising » SLS, posted by Mitch on June 3, 2001, at 12:07:00
My guess is that business considerations and/or legal technicalities could have quashed any interest in following up on this study. I'm not even sure which pharmaceutical company would have worked on a more benign version of nortryptyline, since both Novartis (Pamelor) and Eli Lilly (Aventyl) make branded versions -- not to mention the long-available generics. Interestingly, Nortryp isn't even referenced on their websites.
The fact that this study came out during a period when SSRI's were mushrooming -- and Lilly had to protect cash cow Prozac -- couldn't have helped. Also, competitors could play up the bad press about tricyclics, even if a refined version lacked the side effects and potential lethal overdose hazards. Etc., etc.
Rick
> > Mitch - can you recall about when the article regarding nortriptyline was published?
>
> SLS, It is quite old, but here is the entire
> abstract,
>
> Mitch
>
> Neuropsychobiology 1996;34(1):44-8
>
> Antidepressant and anxiolytic profiles of E-10-hydroxynortriptyline on electrocorticograms of rats.
>
> Nordin C, Krijzer F.
>
> Department of Clinical Neuroscience and Family Medicine, Karolinska Institute, Huddinge University Hospital, Sweden.
>
> Electrocorticograms of rats were recorded after administration of increasing doses of the major metabolite of nortriptyline (NT), E-10-hydroxynortriptyline (E-10-OH-NT). The results were compared with those of NT administration. In visual as well as computerized evaluations, E-10-OH-NT demonstrated clear antidepressant properties, thus confirming previous experiments in depressed patients. There is some evidence that E-10-OH-NT also has an anxiolytic profile. The results with the parent drug NT were not so pronounced. Since E-10-OH-NT has been shown to be devoid of side effects when previously administered to humans, this substance is clearly to be considered of interest for potential development into a new antidepressant. Whether or not the anxiolytic profile is of clinical interest needs to be investigated further.
>
> PMID: 8884759 [PubMed - indexed for MEDLINE]
poster:Rick
thread:64685
URL: http://www.dr-bob.org/babble/20010530/msgs/65263.html